MS treatment across the disease course means thinking beyond individual relapses or a single EDSS score: How early should treatment begin, which strategy fits the individual, and is there really a point when it becomes “too late” to protect meaningful function?
In this interview, Prof. Klaus Schmierer, Professor of Neurology at Queen Mary University of London and honorary consultant neurologist at Barts Health NHS Trust, takes us from the very earliest stages of MS to advanced disability.
We talk about the importance of starting treatment early once the diagnosis is sufficiently secure, why diagnostic accuracy still matters, and what the ATAC-MS study may teach us about intervention within the first weeks after symptoms begin.
We also explore the difference between continuous treatment and immune reconstitution therapies, how risks and benefits need to be weighed over decades rather than months, and why people with advanced MS deserve better evidence and more therapeutic options.
One message runs through the whole conversation: treat early, think long-term – and don’t give up too soon.
You are currently viewing a placeholder content from Default. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationTable of Contents
Early treatment – is there a therapeutic window?
Klaus, could you briefly introduce yourself and tell us what currently drives your work in MS?
Prof. Klaus Schmierer: I’m a Professor of Neurology at Queen Mary University of London and an honorary consultant neurologist at Barts Health NHS Trust.
My work really spans the whole disease course. At one end there is AttackMS, a trial looking at the first weeks after the first symptom suggestive of demyelination. At the other end there is ChariotMS, testing treatment in people with advanced disability.
You could say the unifying question is: when can treatment still change a person’s future?
I want to challenge therapeutic nihilism at both ends of MS and really treat the disease and the person in front of us, rather than merely a label or an EDSS score.
How early does MS need to be treated to make the biggest difference to long-term outcomes?
Prof. Klaus Schmierer: As early as possible, once the diagnosis is sufficiently secure. MS biology starts before the first recognised clinical attack, and early compensation can conceal damage. But that doesn’t make the damage harmless.
Treatment has the greatest potential before irreversible injury and loss accumulate. I often think of MS treatment as secondary prevention: you already have a manifestation of the disease, and then you try to essentially flatten the further progression over time or, ideally, even improve the course.
The treatment window is a gradient. It isn’t like a trapdoor where you are either inside or outside. Rapid disease control matters, but diagnostic accuracy remains essential as well. You don’t want to treat somebody with MS therapies who actually doesn’t have MS.
Sometimes lesions found on MRI are misinterpreted as demyelinating lesions. Young people with migraine, for example, can have quite a few lesions as well. That can create uncertainty and, in some cases, lead to a wrong diagnosis and therefore the wrong treatment.
You can learn more about diagnostic criteria, MRI findings and important differential diagnoses in my episode on how a rapid and clear MS diagnosis can be made.
With studies such as AttackMS, you are looking at very early high-efficacy treatment. What is the key question you want to answer?
Prof. Klaus Schmierer: The key question is whether highly effective treatment within weeks of the first symptoms can alter the disease trajectory.
The fundamental idea is whether very early intervention can lead to a situation where we can say: living with MS, but hardly affected by it. Can rapid suppression of inflammation preserve tissue and neurological function?
There is also a second question that is particularly relevant to the healthcare environment I work in: can the NHS actually identify, assess and treat people this quickly and safely? In AttackMS, the window is 14 days from the very first symptom suggestive of demyelination to the first treatment course.
We use natalizumab because it acts rapidly, not because everyone should remain on it indefinitely. It also has a relatively quick washout if the diagnosis is ultimately not confirmed as MS.
For inclusion in the study, we ask people to have two lesions on their brain MRI that are suggestive of demyelination. Together with a typical clinical syndrome, that gives us an over 80% probability that the person will turn out to have MS. But sometimes that is still not the case. We had somebody in the study who turned out to have an NMOSD spectrum disorder.
That illustrates why, when you narrow the diagnostic and treatment window so much, you don’t necessarily want to commit someone immediately to a treatment with a very long-lasting effect.
The early cohort is encouraging, but comparative trial evidence is the next step. The total duration for participants in the trial is 24 weeks.
One of our co-primary outcomes is whether we are actually able to recruit people within this short timeframe. The second is an MRI measure that we use to infer the degree of repair. It is called magnetisation transfer ratio, a quantitative MRI measure of tissue integrity that is particularly influenced by the myelination status of the tissue.
The idea is to understand to what degree we can remyelinate, or facilitate repair, through such an early intervention.
Do you think we still wait too long before using highly effective therapies in some people with MS?
Prof. Klaus Schmierer: In some people, definitely. But it is also fair to say that practice has improved.
The traditional escalation concept was to start with what we call a modest-efficacy drug, monitor the person and then escalate treatment if additional disease activity occurred.
You can find a general introduction to disease-modifying therapies for MS here.
But if you come back to the idea of secondary prevention, you realise that you are essentially waiting for new damage to happen before stepping up treatment. By the time you escalate, damage with potential long-term consequences has already occurred.
I therefore think highly effective therapy should be discussed very early. That is standard practice where I work, although it is not unequivocally the case across the UK. There is still a lot of heterogeneity, not only within countries but globally.
At the same time, early high-efficacy treatment should not become another rigid ideology. The choice has to reflect disease biology and safety, but also pregnancy plans, comorbidities, lifestyle and the individual person’s willingness to accept particular risks.
Real shared decision-making means offering effective options before deterioration occurs.
How should we treat – continuous therapy or immune reconstitution?
Some treatments are given continuously, while others aim for immune reconstitution. What is the fundamental difference?
For an overview of the different approaches to MS treatment and prevention, you can read this introductory article.
Prof. Klaus Schmierer: Continuous therapies control MS while the treatment and its biological effect are maintained. If you stop the treatment, you can usually assume that the effect will wane, and with some drugs that can happen quite quickly.
We know that after stopping certain treatments, disease activity can return within weeks. In some circumstances, people can even experience severe recurrence or deterioration, sometimes referred to as rebound, where disease activity may be more pronounced than before treatment was started.
Immune reconstitution works differently. You use short treatment courses with the aim of producing disease control beyond the period of drug exposure.
Cladribine and alemtuzumab are examples. With cladribine, for example, treatment is limited to a relatively small number of treatment days across two years, followed by treatment-free years.
The distinction is useful, although it isn’t absolute. Personally, I prefer the term “pulsed immunotherapy” to the more dramatic idea of an “immune reset”. An immune reset is perhaps more appropriate when talking about something like aHSCT (autologous haematopoietic stem cell transplantation).
Which patients may particularly benefit from an immune reconstitution approach – and for whom might it be less suitable?
Prof. Klaus Schmierer: It can be useful for people who need high efficacy and who value freedom from continuous dosing, infusions or taking tablets.
That can be attractive when work, travel, caring responsibilities or access to infusion centres make continuous treatment more burdensome.
It can also be useful to consider in relation to pregnancy planning, once treatment has been completed and the required waiting interval has passed, because you want to avoid treatment while getting pregnant or during pregnancy.
It may be less suitable in the presence of relevant infections, malignancy or concerns about immunosuppression, and of course during pregnancy itself.
There may also be situations where an extremely rapid effect is required. Cladribine, for example, takes around four to six weeks to fully kick in.
And at present it is not necessarily the obvious answer for predominantly non-active MS. But “non-active” really means activity that we cannot detect.
From pathology, we know that in four out of five cases you can still detect inflammatory lesions even at very late stages of disease. These are people who have donated their central nervous system to the MS Tissue Bank here in the UK.
So “activity” is a relative term. Treatment selection is really about finding the right fit rather than declaring one drug the universal winner.
What are the main uncertainties or risks when we try to treat MS strongly and early?
Prof. Klaus Schmierer: What I often say in clinic is that people need to think not only about what is happening now, but project themselves 20 or 30 years into the future. That can obviously be very challenging when you have an 18-year-old sitting in front of you.
We accept an immediate treatment risk in order to prevent an uncertain future. MS has a very broad spectrum in terms of how the disease develops in an individual.
Approximately one in ten people may get away without treatment or with a very mild intervention. But the question is: are you that one in ten, or are you one of the other nine?
The risks of treatment can include infections, impaired vaccine responses, secondary autoimmunity – particularly with some treatments such as alemtuzumab – malignancy signals and reproductive considerations. With highly interventional approaches such as HSCT, there are additional risks.
Long-term comparative evidence is also incomplete, particularly in diverse populations. We have relatively good information about groups of people in studies, but individual prognosis remains challenging.
We also need to understand cumulative immune effects across decades and across different treatment sequences much better.
At the same time, undertreatment carries risks as well: relapses, silent lesions, cognitive decline and loss of neurological reserve.
So the comparison is not simply treatment versus no risk. It is treatment risk versus the risk of insufficiently controlled MS.
In the past, we perhaps placed more emphasis on treatment risk than on the risk of the disease itself. That balance has changed partly because we no longer have such a straightforward correlation between high efficacy and high risk. Many treatment risks have become much more manageable.
It is also important not to assume that somebody with apparently “mild MS” automatically needs mild treatment. Whether a particular loss of function is acceptable is an individual judgement.
Who am I to decide, for example, whether it is insignificant for someone to go from being able to run a marathon to only being able to run half a marathon?
My view of MS on a group level should not determine the decision an individual makes about what risk they are prepared to accept in order to live with MS while being as little affected by it as possible.
Nele: That reminds me of my interview with Dominic Shadbolt. He made the point that perhaps around 10% of people may do well with only mild treatment, but considerably more people believe they belong to that 10%. And that makes these decisions difficult.
And Prof. Barbara Willekens made another important point when we spoke about MS brain health and early treatment: we are quite good at identifying people who are likely to have highly active MS, but much less good at identifying those who will really have a mild disease course.
Prof. Klaus Schmierer: I think an important point is that people often assume that someone with “mild MS” should therefore receive milder treatment, while someone with severe MS should receive a stronger intervention. The latter may well be true, but the former is very much a judgement call and requires a lot of explanation and discussion with the individual.
Who am I to decide what represents a significant impact on somebody’s quality of life? If someone can no longer run a marathon but can still run half a marathon, some people might say, “Well, you can still run half a marathon.” That is an extreme example, but it illustrates the point.
My view of MS on a group level should not determine the decision an individual makes about the risks they are prepared to take in order to maintain the goal of living with MS while being as little affected by it as possible.
Nele: And the definition of mild MS, at least in the past, sometimes included an EDSS of 3.0 after many years. I would not call that mild.
Prof. Klaus Schmierer: Exactly. Studies looking at so-called mild MS have sometimes followed people for ten years and found that a certain proportion were still doing quite well. But if you wait another five or ten years, a considerable number may still end up with substantial disability.
That illustrates the whole problem of trying to predict who will do well and who will not in the future. This is where the discussion about risk becomes so important: what kind of risk is an individual prepared to take?
Overall, treatment risks have come down, or at least become much more manageable, and that is a major achievement, particularly over the last 10 to 15 years.
Advanced MS – when is it really “too late” to treat?
People with advanced disability are often underrepresented in MS trials. Why is that a problem?
Prof. Klaus Schmierer: In short, evidence-based medicine works poorly for people who are excluded from the evidence.
If you do not produce evidence in a particular group and then base your decision-making on the fact that there is no evidence, you have a problem. You need to run trials that actually examine treatment in those people.
Trials commonly impose age and EDSS limits. They may include people up to 50, 55 or sometimes 60 years of age, and they focus heavily on walking.
Once you reach an EDSS of around 3.5 or 4, the EDSS becomes very much a walking scale.
The absence of evidence is too easily converted into the claim that treatment cannot work. But advanced disability does not necessarily mean biologically inactive disease.
When somebody comes into my clinic in a wheelchair, or even an electric wheelchair, I have in mind the pathology evidence showing that in four out of five cases you may still find active lesions – sometimes activity that may not even be reflected on MRI.
The EDSS also underrepresents hand function, cognition, vision, fatigue, pain and participation in life.
The inability to walk does not mean there is little left to protect.
ChariotMS focuses on people with advanced MS and places strong emphasis on arm and hand function. Why is that so important?
Prof. Klaus Schmierer: ChariotMS is a trial in people with advanced MS who would usually be excluded from clinical trials. If you do not produce the evidence, you cannot practise evidence-based medicine for this group.
When walking is severely limited, hand and arm function becomes central to independence: operating a wheelchair, preparing food, eating, dressing, transferring, using a phone or computer – or simply giving someone a hug.
A small loss of function can make the difference between autonomy and dependence.
If somebody comes into my consultation room with an EDSS of eight and has one hand they can use to operate the joystick of their electric wheelchair, that is a function I want to protect as much as I possibly can.
If they lose that function, they still have a valuable life, of course, but their independence may become more limited. That function is worth protecting.
Preserving hand function matters even if the EDSS itself does not change.
The trial is still blinded, so we have to wait for the efficacy results. But one thing the study has already done is help shift the perspective on people with advanced MS.
They have gained more visibility and, hopefully, more hope. We are talking about a substantial proportion of the total population of people living with MS.
The trial has also shown that it is possible to conduct research in this group and that people want to participate. Even if a trial does not meet its primary outcome, signals in secondary outcomes can help shape the next generation of studies. Hopefully this is a population that will no longer routinely be excluded.
Nele: It reminds me of my conversation with Prof. Anthony Feinstein about the CogeX trial in people with progressive MS. They did not achieve the primary outcome they had hoped for, but they still gained important insights – including how valuable staying active can be. And, of course, simply including people with progressive MS in trials is important if we want evidence-based medicine for this group.
Prof. Klaus Schmierer: That’s right. ChariotMS has certainly been a challenging trial. We started recruitment during the COVID period, and testing an immunotherapy during the pandemic was particularly difficult.
But one thing we have already been able to demonstrate is that doing this kind of study is possible. It is also clear that people with advanced MS want these trials. They want the opportunity to participate in research.
When it comes to the results, of course the highest hurdle is always whether the primary outcome is positive. We will have to wait and see.
But even if we find important signals in the secondary outcomes, those results can help shape the next generation of studies. Hopefully, they will also help ensure that people with advanced MS are no longer routinely excluded from clinical trials.
Do we sometimes stop disease-modifying treatment too early simply because someone has reached a high level of disability?
Prof. Klaus Schmierer: Yes. One of the underlying assumptions behind ChariotMS is that disability alone is a poor stopping rule.
A high EDSS score does not prove that inflammation has ended.
You need to consider relapses, MRI activity, progression, age, risks, comorbidities and the functions that are at stake.
Continuing an ineffective or burdensome treatment is obviously not good medicine either. But treatment should be stopped because the biology and the risk-benefit balance support that decision – not simply because somebody uses a wheelchair or has reached a particular birthday.
We need to look more at biological age than calendar age.
It has to be highly individualised. There have already been studies indicating that stopping treatment as a blanket rule is a poor approach, and the consequences may also depend on which treatment a person was receiving before stopping.
Our understanding of the biological effects of the different treatments continues to improve, and that increasingly informs these decisions.
Looking across the whole disease course
Should MS treatment become less about disease categories and more about identifying what function and tissue can still be preserved?
Prof. Klaus Schmierer: This question was not asked separately in the recorded interview. Klaus addressed the underlying point at several stages of the conversation.
A high EDSS score does not prove that inflammation has ended. You need to consider relapses, MRI activity, progression, age, risk, comorbidity and the functions at stake.
Ask what disease remains active and what treatment is trying to protect.
Advanced disability does not mean that nothing meaningful remains to protect. It is not only about walking. Hands, vision, cognition, communication and independence matter.
If we combine what you are studying at the very beginning and at advanced stages of MS, what does that tell us about the idea of a “treatment window”?
Prof. Klaus Schmierer: They examine opposite ends of the same problem.
AttackMS asks whether acting within weeks maximises long-term preservation, with the aim of living with MS but hardly being affected by it.
ChariotMS asks whether the opportunity for treatment has sometimes been declared closed too early in people with advanced disability.
There has been this idea of a “window of therapeutic opportunity”. I think one of the wrong assumptions was that simply because somebody has more disability, they no longer have elements of their disease that could potentially be positively influenced by immunotherapy.
That does not mean immunotherapy is the only intervention. Symptomatic treatments and many other aspects of care are equally important. But advanced disability should not, by default, rule out immunotherapy.
There may actually be several windows for protecting different tissues and functions.
One hypothesis underpinning ChariotMS is that there is a length dependency. Nerve fibres travelling from the brain to the legs have a much longer distance to travel than those involved in arm function, so there are more opportunities for lesions along those pathways to affect function.
We also need to remember that around half of nerve fibres terminate at neck level, giving greater redundancy for upper limb function.
If inflammation in lesions continues to play a role in disease activity and functional impairment, then there may still be something meaningful to protect.
The idea is: treat early, think long-term and do not give up too soon – or never give up.
Which development in the field of MS would you like to see within the next 5 years?
Prof. Klaus Schmierer: I would like to see biomarkers that show us which part of an individual person’s disease remains treatable.
Some of that is already entering clinical practice, but in the UK healthcare environment we still do not routinely have access to things such as neurofilament measurements in blood.
I would also like to see therapies for compartmentalised inflammation in the central nervous system. Most of our available treatments, including high-efficacy drugs, work mainly on the peripheral immune system. They do not necessarily get directly into the brain, where the action in MS is taking place.
Over the past decade, we have learned more about the chronic components of inflammation, and it is probably beneficial if drugs can enter the brain and tackle these processes more directly.
I would also like to see meaningful neuroprotection and repair.
With AttackMS, for example, we are looking at repair very early, within weeks. Many remyelination studies have traditionally been carried out in populations with more advanced disease. But from a pathology perspective, if a nerve fibre has already been lost, you cannot remyelinate it anymore.
So we need to prevent loss earlier without giving up on treatment later.
I would also like to see more trials including older and more disabled people, with outcomes that genuinely matter to them. ChariotMS is one example; the oldest participant enrolled was 80.
Public and patient involvement is becoming increasingly important in shaping this work.
We also need faster pathways from diagnosis to treatment without losing diagnostic accuracy. The new diagnostic criteria will have an impact on that.
And we need better evidence about when to pause treatment, retreat, de-escalate or stop.
Finally, we need equitable access. Breakthroughs only matter if people can actually receive them.
I have been involved with the MS International Federation for a number of years, and moving from clinical evidence and licensing to making treatment accessible to everyone who needs it remains an enormous challenge.
There are countries that do not even have a single MRI scanner. We need to remember that when we talk about advances in MS treatment.
What would you like our listeners – especially people living with MS – to take away from this conversation?
Prof. Klaus Schmierer: MS is serious, but it is increasingly treatable.
We are talking about secondary prevention. Neurological tissue is easier to preserve than to replace. Once a nerve fibre has been lost, we cannot simply replace it. We can only hope that other areas of the brain compensate and take over some of its function.
Ask what disease remains active and what the treatment is trying to protect.
I think the best treatment is an effective option that fits the individual.
And advanced disability does not mean there is nothing meaningful left to protect. It is not only about walking. Hands, vision, cognition, communication and independence matter.
I remain very hopeful, but at the same time we need to insist on honest evidence rather than hype.
Treat early, think long-term and don’t give up.
Farewell
Thank you for being my guest, Klaus. It was a pleasure. I’m looking forward to the results of your trials and to seeing what comes next – and thank you for shining a spotlight on the more disabled parts of the MS community.
Prof. Klaus Schmierer: Thank you very much for inviting me. Hopefully I’ll be back at some point in the future once ChariotMS or the other trials have read out.
Further reading about Klaus Schmierer’s research
See you soon and try to make the best out of your life,
Nele
For more information and positive thoughts, subscribe to my newsletter for free.
Click here for an overview of all podcast episodes published so far.
And at many more places.
* This text contains affiliate links. This means that I get a small compensation if you buy the product recommended by me through the link. For you nothing changes in the price of the product. And it helps me to pay for the blog and to write new posts.






